Acurx Pharmaceuticals, LLC

Nov 19, 2020

Acurx Announces Positive Phase 2A Clinical Trial Results for Ibezapolstat in C. difficile Infection at Prominent International Conference

Jul 23, 2020

Acurx Actively Enrolling Patients in Ph2 Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)

Jan 15, 2020

Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection

Nov 04, 2019

Acurx Pharmaceuticals to Present at Two Prominent International Healthcare Conferences

Oct 03, 2019

Acurx's Novel Lead Antibiotic Candidate Presented at Two Prominent International Scientific Conferences

Feb 27, 2019

Acurx Announces First-In-Man Clinical Trial Data of ACX-362E for CDI

Jan 16, 2019

Acurx Receives FDA Fast Track Designation for ACX-362E for the Treatment of C. difficile infection

Oct 04, 2018

Acurx Pharmaceuticals to Enter Clinical Trials with First-In-Class Antibiotics to Treat Selected Gram-Positive Bacterial Infections

Jun 20, 2018

FDA Grants QIDP Designation to Acurx's Lead Antibiotic Product Candidate, ACX-362E for Clostridium Difficile Infection